New clinical and real world data further confirms the safety profile and efficacy of Lucentis (ranibizumab) and supports a flexible dosing approach

on

Real world data presented by Novartis at the 2014 Association for Research in Vision and Ophthalmology (ARVO) Conference this week further support the well-established safety and efficacy profile…